The model focuses on helping clinicians identify “causes and consequences” of dyspareunia and nonpharmacologic self-care interventions.
A new study highlighted how common sexual dysfunction is among middle-aged persons and if the prevalence among Canadians is consistent with American and British reports.
A recent study quantified how much the treatment effect of pharmacologic modalities for female sexual dysfunction could be attributed to the placebo effect.
Dilator therapy can be extremely successful in treating superficial dyspareunia, but compliance is often poor. A new type of vaginal dilator that gives women more control aims to address the issue.
An oral selective estrogen receptor modulator approved for treatment of mild to moderate dyspareunia in menopausal women reduced signs and symptoms of atrophy in the vulva, vestibule, urethral meatus and vagina region, according to results of a prospective open-label pilot study
In women with endometriosis, deep dyspareunia is associated with lower sexual quality of life (QoL), according to a study.
Although gabapentin is recommended and commonly prescribed for vulvodynia, its value in such cases is usually associated with complaints that have neuropathic components, such as dynamic allodynia.
The experimental agent TX-004HR effectively improved the vaginal mucosa of postmenopausal women with vulvovaginal atrophy (VVA) and reduced moderate-to-severe dyspareunia and vaginal dryness compared to placebo, according to results of a trial.
Understanding the psychological underpinnings of sexual motivation can be helpful in improving the sexual and relationship well-being of couples affected by vulvodynia, according to recent research.
A small study shows that treatment with CO2 laser induces histological changes in the epithelium and lamina propria that may result in improvement in symptoms associated with vulvovaginal atrophy (VVA).